NCT01867424View on ClinicalTrials.gov

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 14, 2013

Primary Completion Date

May 30, 2016

Study Completion Date

December 8, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Eovist

0.1 ml/kg Eovist will be administered intravenous (IV) to each patient

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01867424 - Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer | Biotech Hunter | Biotech Hunter